Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Etienne Paubelle(Lyon 1 Université), Xavier Thomas(Hôpital Lyon Sud), Gilles Salles(Memorial Sloan Kettering Cancer Center), Eric Wattel(Université Claude Bernard Lyon 1), Sophie Ducastelle-Leprêtre(Hospices Civils de Lyon), Franck E. Nicolini(Hôpital Lyon Sud), Adriana Pleșa(Hospices Civils de Lyon), Hélène Labussière‐Wallet, Fiorenza Barraco(Hôpital Lyon Sud)
Cited by 10
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603